chr19-12810402-A-G
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 6P and 2B. PM1PM2PM5BP4_Moderate
The ENST00000221486.6(RNASEH2A):āc.635A>Gā(p.Asn212Ser) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000459 in 1,613,584 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/25 in silico tools predict a benign outcome for this variant. 2/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Uncertain significance (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N212I) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000221486.6 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RNASEH2A | NM_006397.3 | c.635A>G | p.Asn212Ser | missense_variant, splice_region_variant | 6/8 | ENST00000221486.6 | NP_006388.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RNASEH2A | ENST00000221486.6 | c.635A>G | p.Asn212Ser | missense_variant, splice_region_variant | 6/8 | 1 | NM_006397.3 | ENSP00000221486 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000789 AC: 12AN: 152170Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000716 AC: 18AN: 251418Hom.: 0 AF XY: 0.0000883 AC XY: 12AN XY: 135882
GnomAD4 exome AF: 0.0000424 AC: 62AN: 1461414Hom.: 0 Cov.: 32 AF XY: 0.0000481 AC XY: 35AN XY: 727060
GnomAD4 genome AF: 0.0000789 AC: 12AN: 152170Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74336
ClinVar
Submissions by phenotype
Aicardi-Goutieres syndrome 4 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 27, 2022 | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 212 of the RNASEH2A protein (p.Asn212Ser). This variant is present in population databases (rs377244188, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with RNASEH2A-related conditions. ClinVar contains an entry for this variant (Variation ID: 1007176). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 26, 2022 | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 25, 2021 | The c.635A>G (p.N212S) alteration is located in exon 6 (coding exon 6) of the RNASEH2A gene. This alteration results from a A to G substitution at nucleotide position 635, causing the asparagine (N) at amino acid position 212 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at